# The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Study · id `cardio:ct-nct01135212` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01135212](<https://clinicaltrials.gov/study/NCT01135212>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01135212

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 290 participants.

## Technical summary

Registry record NCT01135212. Randomized; triple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 290 participants (enrolled count; ClinicalTrials.gov record NCT01135212, source copy `cardio:ctgov-nct01135212-2012-08-24`, retrieved 2026-10-26)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01135212, source copy `cardio:ctgov-nct01135212-2012-08-24`, retrieved 2026-10-26)
- Primary completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01135212, source copy `cardio:ctgov-nct01135212-2012-08-24`, retrieved 2026-10-26)
- Completion: 2011-05 (actual) (ClinicalTrials.gov record NCT01135212, source copy `cardio:ctgov-nct01135212-2012-08-24`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01135212, source copy `cardio:ctgov-nct01135212-2012-08-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01135212-2012-08-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): Fimasartan 60mg
- Intervention (Drug): Fimasartan 120mg
- Intervention (Drug): Candesartan cilexetil
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Kyungpook National University Hospital
- Collaborator class: OTHER
- Collaborator: Gyeongsang National University Hospital
- Collaborator class: OTHER
- Collaborator: Keimyung University
- Collaborator class: OTHER
- Collaborator: Kosin University Gospel Hospital
- Collaborator class: OTHER
- Collaborator: Daegu Catholic University Medical Center
- Collaborator class: OTHER
- Collaborator: Dong-A medical center
- Collaborator class: UNKNOWN
- Collaborator: Pusan National University Yangsan Hospital
- Collaborator class: OTHER
- Collaborator: Yeungnam University Hospital
- Collaborator class: OTHER
- Collaborator: Ulsan University Hospital
- Collaborator class: OTHER
- Collaborator: Inje University
- Collaborator class: OTHER
- Collaborator: Pusan National University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Candesartan (`cardio:candesartan`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: Kyungpook National University Hospital (`cardio:org-kyungpook-national-university-hospital`)
- Registry lists this organization as a collaborator: Gyeongsang National University Hospital (`cardio:org-gyeongsang-national-university-hospital`)
- Registry lists this organization as a collaborator: Kosin University Gospel Hospital (`cardio:org-kosin-university-gospel-hospital`)
- Registry lists this organization as a collaborator: Daegu Catholic University Medical Center (`cardio:org-daegu-catholic-university-medical-center`)
- Registry lists this organization as a collaborator: Pusan National University Yangsan Hospital (`cardio:org-pusan-national-university-yangsan-hospital`)
- Registry lists this organization as a collaborator: Yeungnam University Hospital (`cardio:org-yeungnam-university-hospital`)
- Registry lists this organization as a collaborator: Ulsan University Hospital (`cardio:org-ulsan-university-hospital`)
- Registry lists this organization as a collaborator: Inje University (`cardio:org-inje-university`)
- Registry lists this organization as a collaborator: Pusan National University Hospital (`cardio:org-pusan-national-university-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension (`cardio:pubmed-27161546`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8eeb4bbcbd4a24a9dd010825905bdd0f9d65429ce4a0811069eff9ef4d1f8180
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
